Trump Was Right: Study Shows Hydroxychloroquine Boosted Ventilated COVID Patients’ Survival by 200%


A new study seems to confirm that former President Donald Trump may very well have been right about hydroxychloroquine.

According to the observational study published on MedRxiv that surveyed 255 patients infected with the coronavirus and requiring intermittent mandatory ventilation, weight-adjusted hydroxychloroquine and azithromycin improved the survival of such patients by nearly 200 percent.

“Most Covid studies have not considered days of therapy, cumulative dose, or weight-adjusted dosing. We found that when the cumulative doses of two drugs, HCQ and AZM, were above a certain level, patients had a survival rate 2.9 times the other patients,” the study noted in its conclusion.

Posted on May 31, the research is currently a preprint, meaning it has yet to be peer reviewed.

That being the case, the results of this study are incredibly promising according to The Western Journal’s expert medical contributor, Omar L. Hamada, MD.

“As more unfiltered evidence comes out on the origins, prevalence, disease progression, and treatment of COVID, we begin to see a clearer picture,” Hamada said.

“One not unlike original suspicions driven by actual science instead of one manufactured and spun by a government and media intent on manipulation and economic and societal destruction through a fear-driven agenda.”

During the pandemic, Trump was a vocal supporter of using hydroxychloroquine as a treatment for COVID-19.

The former president even took a two-week regimen of the anti-malarial drug after he had been diagnosed with COVID.

Read more…

Sponsored Links

Comments are closed.